Beneficial effect of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on energy metabolism in ischemic dog hearts.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Archives internationales de pharmacodynamie et de therapie

• Publication date

  1996-03-01

• Fields of study

  Medicine

• Identifiers
  PMID 8937627
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Propionyl L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation.

  1995cited by this paper
• Effect of L-carnitine on the cellular distribution of carnitine and its acyl derivatives in the ischemic heart.

  1992cited by this paper
• Protection of the reperfused heart by L-propionylcarnitine.

  1991cited by this paper
• Response of isolated working hearts to fatty acids and carnitine palmitoyltransferase I inhibition during reduction of coronary flow in acutely and chronically diabetic rats.

  1989cited by this paper
• Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation.

  1989cited by this paper
• Etomoxir, a Carnitine Palmitoyltransferase I Inhibitor, Protects Hearts From Fatty Acid‐Induced Ischemic Injury Independent of Changes in Long Chain Acylcarnitine

  1988cited by this paper
• Effects of L-propionylcarnitine on mechanical recovery during reflow in intact hearts.

  1988cited by this paper
• 3-(2,2,2-Trimethylhydrazinium)propionate (THP)--a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties.

  1988cited by this paper
• Accumulation of lipids and lipid-intermediates in the heart during ischaemia.

  1987cited by this paper
• On the possible role of long chain fatty acylcarnitine accumulation in producing functional and calcium permeability changes in membranes during myocardial ischaemia.

  1987cited by this paper
• Effects of the fatty acid blocking agents, oxfenicine and 4-bromocrotonic acid, on performance in aerobic and ischemic myocardium.

  1987cited by this paper
• Lysophospholipids, long chain acylcarnitines and membrane dysfunction in the ischaemic heart.

  1987cited by this paper
• Protection of the ischaemic myocardium by L-propionylcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport, and fatty acid oxidation.

  1986cited by this paper
• High-performance liquid chromatographic method for the simultaneous determination of myocardial creatine phosphate and adenosine nucleotides.

  1984cited by this paper
• Effects of Diltiazem and Propranolol on Irreversibility of Ischemic Cardiac Function and Metabolism in the Isolated Perfused Rat Heart

  1983cited by this paper
• Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart.

  1981cited by this paper
• Protection of the ischemic dog myocardium with carnitine.

  1978cited by this paper
• Glycogen metabolism and the effect of nitroglycerin on the glycogen metabolism in the normal and ischemic canine myocardium

  1975cited by this paper
• Adenosine triphosphate conservation in metabolic regulation. Rat liver citrate cleavage enzyme.

  1967cited by this paper

• Inhibited Carnitine Synthesis Causes Systemic Alteration of Nutrient Metabolism in Zebrafish

  2018cites this paper
• eview harmacological effects of meldonium : Biochemical mechanisms and iomarkers of cardiometabolic activity

  2016cites this paper
• Pharmacological effects of meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity.

  2016cites this paper
• [[Meldonium in treatment of patients with myocardial infarction].

  2014cites this paper
• Mildronate in cardiology practice – current evidence, ongoing research, and future perspectives

  2012cites this paper
• MOLECULAR MECHANISMS OF CARBOHYDRATE METABOLISM- RELATED DISORDERS: INVESTIGATION IN EXPERIMENTAL MODELS AND CLINICAL SAMPLES Summary of thesis for obtaining the degree of a Doctor of Pharmacy

  2012cites this paper
• Anti-diabetic effects of mildronate alone or in combination with metformin in obese Zucker rats.

  2011cites this paper
• The Regulation of Energy Metabolism Pathways Through L-Carnitine Homeostasis

  2011cites this paper
• Role of the Adipocyte in Development of Type 2 Diabetes

  2011cites this paper
• Myocardial Infarct Size-Limiting and Anti-Arrhythmic Effects of Mildronate Orotate in the Rat Heart

  2009cites this paper
• Mildronate decreases carnitine availability and up-regulates glucose uptake and related gene expression in the mouse heart.

  2008cites this paper
• Mildronate, a Novel Fatty Acid Oxidation Inhibitor and Antianginal Agent, Reduces Myocardial Infarct Size Without Affecting Hemodynamics

  2006cites this paper
• Mildronate, an Inhibitor of Carnitine Biosynthesis, Induces an Increase in Gamma-Butyrobetaine Contents and Cardioprotection in Isolated Rat Heart Infarction

  2006cites this paper
• Mildronate: an antiischemic drug for neurological indications.

  2006cites this paper
• Ranolazine:an Antiischemic Drug with a Novel Mechanism of Action

  2006cites this paper
• MET-88: SR Ca2+-uptake stimulator for treating chronic heart failure

  2006cites this paper
• MILDRONATE: AN ANTIISCHEMIC DRUG WITH MULTIPLE INDICATIONS

  2006cites this paper
• Effectors of fatty acid oxidation reduction: promising new anti-ischaemic agents.

  2005cites this paper
• [The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction].

  2003cites this paper
• The Use of Partial Fatty Acid Oxidation Inhibitors for Metabolic Therapy of Angina Pectoris and Heart Failure

  2002cites this paper
• Mildronate: cardioprotective action through carnitine-lowering effect.

  2002cites this paper
• Cardioprotective Effects of MET-88, a Gamma-Butyrobetaine Hydroxylase Inhibitor, on Cardiac Dysfunction Induced by Ischemia/Reperfusion in Isolated Rat Hearts

  2000cites this paper
• Effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on tissue carnitine and lipid levels in rats.

  2000cites this paper
• Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction.

  2000cites this paper
• Pharmacokinetic Analysis of the Cardioprotective Effect of 3-( 2 , 2 , 2-Trimethylhydrazinium ) Propionate in Mice : Inhibition of Carnitine Transport in Kidney 1

  1999cites this paper
• Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2, 2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney.

  1999cites this paper
• Beneficial effects of MET‐88 on left ventricular dysfunction and hypertrophy with volume overload in rats

  1999cites this paper
• Cardioprotective profile of MET‐88, an inhibitor of carnitine synthesis, and insulin during hypoxia in isolated perfused rat hearts

  1998cites this paper
• Effect of MET‐88, a γ‐butyrobetaine hydroxylase inhibitor, on myocardial derangements induced by hydrogen peroxide in the isolated perfused rat heart

  1997cites this paper